AKTS (Aktis Oncology) Buyback Yield %: -21.63 (As of Jul. 11, 2026)


AKTS Aktis Oncology Inc AKTS
9 GF Score
Price $27.88
View Full Analysis

What is Aktis Oncology Buyback Yield %?

Aktis Oncology AKTS -1.90% 9 Buyback Yield % is -21.63 as of Jul. 11, 2026. GuruFocus rates AKTS with a GF Score™ of 9/100. Among 742 Biotechnology companies, Aktis Oncology ranks worse than 69% on this metric.

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Aktis Oncology's current buyback yield was -21.63%.

Aktis Oncology Buyback Yield % Historical Data

* Premium members only.

The historical data trend for Aktis Oncology's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aktis Oncology Buyback Yield % Chart

Aktis Oncology Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Buyback Yield %
0.00 0.00 0.00 0.00

Aktis Oncology Quarterly Data
Dec22 Dec23 Sep24 Dec24 Mar25 Sep25 Dec25 Mar26
Buyback Yield % Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 -34.36

AKTS vs ZBIO, MLTX, AVBP: Buyback Yield % Comparison

For the Biotechnology subindustry, Aktis Oncology's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aktis Oncology Buyback Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aktis Oncology's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Aktis Oncology's Buyback Yield % falls into.


AKTS
9GF Score
Aktis Oncology Inc AKTS
Buyback Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aktis Oncology Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Aktis Oncology's Buyback Yield for the fiscal year that ended in Dec. 2025 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 0) / 0
=N/A%

Aktis Oncology's annualized Buyback Yield for the quarter that ended in Mar. 2026 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (0 + 339.78) / 988.88764
=-34.36%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Frequently Asked Questions Learn more about Buyback Yield % →
What does a Buyback Yield % of -21.63 mean?
Aktis Oncology (AKTS) has a Buyback Yield % of -21.63 as of Jul. 11, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Aktis Oncology and its competitors. According to the industry distribution chart, Aktis Oncology ranks #512 out of 742 companies in the Biotechnology industry, placing it in the top 69%.
Is Aktis Oncology's Buyback Yield % too high?
Aktis Oncology's current Buyback Yield % is -21.63. Based on the distribution chart, Aktis Oncology ranks #512 out of 742 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Aktis Oncology has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Aktis Oncology's Buyback Yield % compare to ZBIO and MLTX?
According to the Biotechnology industry distribution chart, Aktis Oncology ranks #512 out of 742 companies for Buyback Yield %. This places Aktis Oncology in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Aktis Oncology and its competitors. Aktis Oncology's current Buyback Yield % is -21.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aktis Oncology stock overvalued right now?
Aktis Oncology (AKTS) has a current Buyback Yield % of -21.63. The current Buyback Yield % is -21.63. Aktis Oncology's overall GF Score™ is 9/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Aktis Oncology (AKTS), the current Buyback Yield % is -21.63 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aktis Oncology Business Description

Address 17 Drydock Avenue, Suite 17-401, Boston, MA, USA, 02210
Aktis Oncology Inc is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company specializes in developing targeted alpha radiopharmaceuticals for solid tumors such as breast, lung, colorectal, bladder, and liver cancers. Its pipeline products include AKY-1189 and AKY-2519, focusing on solid tumors. The company has one operating and reportable segment focused on the research and development of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers. The company generates revenue from Collaboration agreement.
9GF Score

Get the complete analysis for AKTS

Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$27.88
Price